Erica Boiman Johnstone

Erica Boiman Johnstone

Auto-generated profile, based on publicly available information

Erica Boiman Johnstone

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Utah School of Medicine , Salt Lake City, UT 84112

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2016 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
BHBrent Hanson
Brent Hanson
EJErica Johnstone
Erica Johnstone
JDJessie Dorais
Jessie Dorais
BSBob Silver
Bob Silver
MPMatthew Peterson
Matthew Peterson
JHJames Hotaling
James Hotaling

18 January 2022 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
RLRichard S. Legro
Richard S. Legro
KHKarl R. Hansen
Karl R. Hansen
MDMichael P. Diamond
Michael P. Diamond
ASAnne Z. Steiner
Anne Z. Steiner
CCChristos Coutifaris
Christos Coutifaris
FNfor the Reproductive Medicine Network
for the Reproductive Medicine Network
Background: Women with obesity and infertility are counseled to lose weight prior to conception and infertility treatment to improve pregnancy rates and birth outcomes, although confirmatory evidence from randomized trials is lacking. We assessed whether a preconception intensive lifestyle intervention with acute weight loss is superior to a weight neutral intervention at achieving a healthy live birth. Methods and findings: In this open-label, randomized controlled study (FIT-PLESE), 379 women with obesity (BMI ≥ 30 kg/m2) and unexplained infertility were randomly assigned in a 1:1 ratio to 2 preconception lifestyle modification groups lasting 16 weeks, between July 2015 and July 2018 (final follow-up September 2019) followed by infertility therapy. The primary outcome was the healthy live birth (term infant of normal weight without major anomalies) incidence. This was conducted at 9 academic health centers across the United States. The intensive group underwent increased physical activity and weight loss (target 7%) through meal replacements and medication (Orlistat) compared to a standard group with increased physical activity alone without weight loss. This was followed by standardized empiric infertility treatment consisting of 3 cycles of ovarian stimulation/intrauterine insemination. Outcomes of any resulting pregnancy were tracked. Among 191 women randomized to standard lifestyle group, 40 dropped out of the study before conception; among 188 women randomized to intensive lifestyle group, 31 dropped out of the study before conception. All the randomized women were included in the intent-to-treat analysis for primary outcome of a healthy live birth. There were no significant differences in the incidence of healthy live births [standard 29/191(15.2%), intensive 23/188(12.2%), rate ratio 0.81 (0.48 to 1.34), P = 0.40]. Intensive had significant weight loss compared to standard (−6.6 ± 5.4% versus −0.3 ± 3.2%, P < 0.001). There were improvements in metabolic health, including a marked decrease in incidence of the metabolic syndrome (baseline to 16 weeks: standard: 53.6% to 49.4%, intensive 52.8% to 32.2%, P = 0.003). Gastrointestinal side effects were significantly more common in intensive. There was a higher, but nonsignificant, first trimester pregnancy loss in the intensive group (33.3% versus 23.7% in standard, 95% rate ratio 1.40, 95% confidence interval [CI]: 0.79 to 2.50). The main limitations of the study are the limited power of the study to detect rare complications and the design difficulty in finding an adequate time matched control intervention, as the standard exercise intervention may have potentially been helpful or harmful. Conclusions: A preconception intensive lifestyle intervention for weight loss did not improve fertility or birth outcomes compared to an exercise intervention without targeted weight loss. Improvement in metabolic health may not translate into improved female fecundity. Trial registration: ClinicalTrials.gov NCT02432209.

1 November 2014 in Reproductive Toxicology
Verified
Journal Article
Closed access
EJErica B. Johnstone
Erica B. Johnstone
GLGermaine M. Buck Louis
Germaine M. Buck Louis
PPPatrick J Parsons
Patrick J Parsons
ASAmy J. Steuerwald
Amy J. Steuerwald
CPChristopher D. Palmer
Christopher D. Palmer
CPC. Matthew Peterson
C. Matthew Peterson

1 July 2018 in Translational Andrology and Urology
Verified
Journal Article
Closed access
PDF file
YIYetunde Ibrahim
Yetunde Ibrahim
EJErica Johnstone
Erica Johnstone
There are several known causes of recurrent pregnancy loss (RPL) in a couple, which include endocrine abnormalities, immunologic abnormalities, structural uterine abnormalities and karyotype abnormalities. The evaluation largely focuses on the female. The male contribution to RPL remains understudied. With the exception of the karyotype analysis, there is currently no other recommended testing for the male partner of a woman who has suffered multiple pregnancy losses. Chromosomal abnormalities are well defined causes of pregnancy losses in the literature. However, despite the fact that abnormal DNA fragmentation has been implicated in the pathogenesis of unexplained RPL, it is not routinely checked during the evaluation of RPL. This is likely due to the fact that abnormal DNA fragmentation is the end result of multiple different mechanisms including environmental exposures, varicoceles, gene alteration and epigenetic changes resulting in an inherent susceptibility to DNA damage? We are just beginning to scratch the surface of our understanding of the male contribution to RPL and more studies especially focusing on epigenetic modifications and gene alterations are needed.

12 November 2019 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
ESEnrique F Schisterman
Enrique F Schisterman
TCTraci Clemons
Traci Clemons
MPMatthew Peterson
Matthew Peterson
EJErica Johnstone
Erica Johnstone
AHAhmad O Hammoud
Ahmad O Hammoud
SMSunni L Mumford
Sunni L Mumford
The Folic Acid and Zinc Supplementation Trial (FAZST) was a multicenter, double-blind, block-randomized, placebo-controlled trial to determine whether folic acid and zinc supplementation in men improves semen quality and increases livebirth rate among couples seeking infertility treatment (2013–2017). Eligible men were aged 18 years or older with female partners aged 18–45 years, seeking infertility treatment. Men were randomized (1:1) to 5 mg folic acid and 30 mg elemental zinc daily or matching placebo for 6 months. Randomization was stratified by site and intended infertility treatment (in vitro fertilization (IVF), non-IVF/study site, and non-IVF/outside clinic). Follow-up of men continued for 6 months, and female partners were passively followed for a minimum of 9 months. Women who conceived were followed throughout pregnancy. Overall, 2,370 men were randomized during 2013–2017 (1,185 folic acid and zinc, 1,185 placebo); they had a mean age of 33 years and body mass index (weight (kg)/height (m)2) of 29.8. Most participants were white (82%), well educated (83% with some college), and employed (72%). Participant characteristics were balanced across intervention arms. Study visits were completed by 89%, 77%, and 75% of men at months 2, 4, and 6, respectively. Here we describe the study design, recruitment, data collection, lessons learned, and baseline participant characteristics.

30 April 2011 in Fertility and Sterility
Verified
Journal Article
Closed access
PDF file
HSHarsha Sharma
Harsha Sharma
EJErica B. Johnstone
Erica B. Johnstone
EGElena Gates
Elena Gates
SSSae H. Sohn
Sae H. Sohn
HHHeather G. Huddleston
Heather G. Huddleston
VFVictor Y. Fujimoto
Victor Y. Fujimoto